CN110559484A - Application of liquid medicine in preparing medicine for improving body shape and posture symptoms - Google Patents

Application of liquid medicine in preparing medicine for improving body shape and posture symptoms Download PDF

Info

Publication number
CN110559484A
CN110559484A CN201910194565.0A CN201910194565A CN110559484A CN 110559484 A CN110559484 A CN 110559484A CN 201910194565 A CN201910194565 A CN 201910194565A CN 110559484 A CN110559484 A CN 110559484A
Authority
CN
China
Prior art keywords
liquid medicine
injection
parts
lymph
symptoms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201910194565.0A
Other languages
Chinese (zh)
Inventor
崔海茹
崔海勇
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Oubang Medical Management Co Ltd
Original Assignee
Shanghai Oubang Medical Management Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Oubang Medical Management Co Ltd filed Critical Shanghai Oubang Medical Management Co Ltd
Priority to CN201910194565.0A priority Critical patent/CN110559484A/en
Publication of CN110559484A publication Critical patent/CN110559484A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
    • A61L27/24—Collagen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/3637—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the origin of the biological material other than human or animal, e.g. plant extracts, algae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M35/00—Devices for applying media, e.g. remedies, on the human body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/31—Details
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/204—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials with nitrogen-containing functional groups, e.g. aminoxides, nitriles, guanidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/30—Compounds of undetermined constitution extracted from natural sources, e.g. Aloe Vera
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/402—Anaestetics, analgesics, e.g. lidocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2400/00—Materials characterised by their function or physical properties
    • A61L2400/06—Flowable or injectable implant compositions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Molecular Biology (AREA)
  • Botany (AREA)
  • Vascular Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Media Introduction/Drainage Providing Device (AREA)

Abstract

The application discloses an application of a liquid medicine in preparing a medicine for improving body type and posture symptoms, the liquid medicine comprises the liquid medicine, and the liquid medicine injected into a lymph stasis blocking area comprises the following raw material components in parts by weight: 1-3 parts of medical collagen filling agent, 2-6 parts of astragalus injection, 2-6 parts of compound angelica injection and 100-300 parts of normal saline. The liquid medicine is applied to preparing the medicines for improving body type and body state symptoms, can be used for injecting compound nutrient solution rich in collagen, angelica injection and normal saline into areas with lymph stasis, and can be used for improving body type and body state symptoms.

Description

Application of liquid medicine in preparing medicine for improving body shape and posture symptoms
Technical Field
The application relates to the field of medical cosmetology, in particular to application of a liquid medicine in preparing a medicine for improving body type and posture symptoms.
background
The lymphatic system is an important defense function system in the human body, and is distributed throughout the whole body, with 7 and 800 lymph nodes. The lymphatic system, on the one hand, drains lymph fluid and removes foreign matters, bacteria and the like in the body. On the other hand, the lymphatic system is a sentinel of body defense, and is dispersed in lymph nodes of various parts of the body like a filtering device, so that microorganisms entering through lymphatic vessels can be effectively prevented. More and more people pay attention to the toxin which is a main source of health hazard, and the lymphatic system plays an important role in the detoxification of human bodies. For example, the inguinal lymph is the largest detoxification system of the entire reproductive system.
In a healthy human body, about one billion lymphocytes are active, and the lymphocytes are classified into T lymphocytes and B lymphocytes. Both are derived from bone marrow, but T cells are formed in the thymus, whose primary function is to phagocytose foreign invaders. The most important function of B cells is to produce a wide variety of antibodies, like weapons within teams, in order to defend us against foreign invaders. The lymphatic circulation gives the toxin sufficient opportunity to contact the surface of the powerful detoxifying cells of the human body. More than 99% of the soluble toxins and metabolic waste products can be removed by the lymphatic system. If accumulated toxins are the root cause of disease, detoxification construction is the starting point for health. The lymphatic system of the human body is very massive, with shoulder and neck, axillary and inguinal lymphatics being the most responsive to health.
Aiming at the problem that the related art lacks of application in medicines for effectively improving body shape and posture, an effective solution is not provided at present.
Disclosure of Invention
The main purpose of the present application is to provide a drug solution for use in the preparation of a drug for ameliorating symptoms of body type and posture.
in order to achieve the above object, according to one aspect of the present application, there is provided a use of a liquid medicine for preparing a medicine for improving body type and posture symptoms, the liquid medicine being injected into a lymph stasis area, comprising the steps of:
Determining an injection position: selecting the position of the lymph stasis blocking area as an injection position;
Skin disinfection: disinfecting the skin at the injection site with a sterile cotton swab;
Liquid medicine injection: and (3) holding the syringe filled with the liquid medicine by hand, evacuating air, aligning the needle tip with the injection position, quickly puncturing the skin, slowly inserting the needle to the needle insertion depth, slowly injecting the liquid medicine, after the liquid medicine is injected, pulling out the needle head of the syringe, and lightly pressing by using a sterile cotton swab to finish injection.
Furthermore, the frequency of injecting the liquid medicine into the lymph stasis blocking area is at least 3 times, the frequency of injection of the first 3 times is 40-60 days, and the frequency of injection of more than 3 times is 3-4 months.
Further, the liquid medicine comprises the following raw material components in parts by weight: 1-3 parts of medical collagen filling agent, 2-6 parts of astragalus injection, 2-6 parts of compound angelica injection and 100-300 parts of normal saline.
Further, the liquid medicine comprises, by weight, 1 part of a medical collagen filler, 2 parts of an astragalus injection, 2 parts of a compound angelica injection and 100 parts of normal saline.
Further, the medical collagen filler is a physiological saline suspension of 3.5% of bovine collagen and 0.3% of lidocaine hydrochloride.
further, the depth of the needle insertion is 3-5 cm.
Further, the subcutaneous tissue is penetrated at an oblique angle of 60 to 90 degrees to the skin surface.
Furthermore, the volume of the liquid medicine injected into the lymph stasis blocking area at one time is not more than 120 ml.
Furthermore, the liquid medicine is prepared for use at present.
Further, the effective components of the compound angelica injection are angelica, ligusticum chuanxiong hort and safflower.
The compound nutrient solution rich in collagen, angelica injection and normal saline is injected into the area of lymph stasis blockage as liquid medicine to be applied to the preparation of medicines for improving symptoms of body type and body state, so that the body type and the body state can be improved. Wherein the collagen increases the firmness and elasticity of the skin, and tensions the skin. The angelica can enrich and activate blood, accelerate blood and lymph circulation, quickly remove toxin and remove stasis and blockage. Dredging channels and collaterals, invigorating qi and blood, relieving the burden of five internal organs, and achieving the effects of coordinating yin and yang balance and shaping perfect body shape.
Detailed Description
In order to make the technical solutions better understood by those skilled in the art, the technical solutions in the embodiments of the present application will be clearly and completely described below with reference to the drawings in the embodiments of the present application, and it is obvious that the described embodiments are only partial embodiments of the present application, but not all embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present application.
It should be noted that the embodiments and features of the embodiments in the present application may be combined with each other without conflict. The present application will be described in detail below with reference to the embodiments with reference to the attached drawings.
Example 1
A liquid medicine is used for preparing a medicine for improving body type and posture symptoms, and is injected into a lymph stasis blocking area, and the method comprises the following steps: determining an injection position: selecting the position of the lymph stasis blocking area as an injection position; skin disinfection: disinfecting the skin at the injection site with a sterile cotton swab; liquid medicine injection: and (3) holding the syringe filled with the liquid medicine by hand, evacuating air, aligning the needle tip with the injection position, quickly puncturing the skin, slowly inserting the needle to the needle insertion depth, slowly injecting the liquid medicine, after the liquid medicine is injected, pulling out the needle head of the syringe, and lightly pressing by using a sterile cotton swab to finish injection. Wherein, the frequency of injecting the liquid medicine into the shoulder and neck lymph area of the lymph stasis area is 10 times, the frequency of injecting the liquid medicine into the shoulder and neck lymph area of the lymph stasis area is 60 days for one time, and the frequency of injecting the liquid medicine into the shoulder and neck lymph area of the lymph stasis area is 4 months for one time when the liquid medicine is more than 3 times. The first 3 times are treatment periods, and beyond 3 times, a maintenance metabolic period is entered.
Example 2
A liquid medicine is used for preparing a medicine for improving body type and posture symptoms, and is injected into a lymph stasis blocking area, and the method comprises the following steps: determining an injection position: selecting the position of the lymph stasis blocking area as an injection position; skin disinfection: disinfecting the skin at the injection site with a sterile cotton swab; liquid medicine injection: and (3) holding the syringe filled with the liquid medicine by hand, evacuating air, aligning the needle tip with the injection position, quickly puncturing the skin, slowly inserting the needle to the needle insertion depth, slowly injecting the liquid medicine, after the liquid medicine is injected, pulling out the needle head of the syringe, and lightly pressing by using a sterile cotton swab to finish injection. Wherein, the frequency of injecting the liquid medicine into the shoulder and neck lymph area of the lymph stasis area is 10 times, the frequency of injecting the liquid medicine into the shoulder and neck lymph area of the lymph stasis area is 60 days for one time, and the frequency of injecting the liquid medicine into the shoulder and neck lymph area of the lymph stasis area is 3 months for one time when the liquid medicine is more than 3 times. The first 3 times are treatment periods, and beyond 3 times, a maintenance metabolic period is entered.
Wherein, the frequency of injecting the liquid medicine to the shoulder and neck lymph areas of the lymph stasis area is 5 times, the frequency of injecting the liquid medicine to the shoulder and neck lymph areas of the lymph stasis area is 40-60 days for the first 3 times, and the frequency of injecting the liquid medicine to the 4 th and 5 th times is 3-4 months for one time. The first 3 times are treatment periods, and beyond 3 times, a maintenance metabolic period is entered.
Example 3
A liquid medicine is used for preparing a medicine for improving body type and posture symptoms, and is injected into a lymph stasis blocking area, and the method comprises the following steps: determining an injection position: selecting the position of the lymph stasis blocking area as an injection position; skin disinfection: disinfecting the skin at the injection site with a sterile cotton swab; liquid medicine injection: and (3) holding the syringe filled with the liquid medicine by hand, evacuating air, aligning the needle tip with the injection position, quickly puncturing the skin, slowly inserting the needle to the needle insertion depth, slowly injecting the liquid medicine, after the liquid medicine is injected, pulling out the needle head of the syringe, and lightly pressing by using a sterile cotton swab to finish injection. Wherein, the frequency of injecting the liquid medicine into the axillary lymph stasis area of the lymph stasis area is 10 times, the frequency of injecting the liquid medicine into the axillary lymph stasis area of the lymph stasis area is 40 days, and the frequency of injecting the liquid medicine into the axillary lymph stasis area of the lymph stasis area is 3 months. The first 3 times are treatment periods, and beyond 3 times, a maintenance metabolic period is entered.
Example 4
A liquid medicine is used for preparing a medicine for improving body type and posture symptoms, and is injected into a lymph stasis blocking area, and the method comprises the following steps: determining an injection position: selecting the position of the lymph stasis blocking area as an injection position; skin disinfection: disinfecting the skin at the injection site with a sterile cotton swab; liquid medicine injection: and (3) holding the syringe filled with the liquid medicine by hand, evacuating air, aligning the needle tip with the injection position, quickly puncturing the skin, slowly inserting the needle to the needle insertion depth, slowly injecting the liquid medicine, after the liquid medicine is injected, pulling out the needle head of the syringe, and lightly pressing by using a sterile cotton swab to finish injection. Wherein, the frequency of injecting the liquid medicine into the axillary lymph stasis area of the lymph stasis area is 10 times, the frequency of injecting the liquid medicine into the axillary lymph stasis area of the lymph stasis area is 40 days, and the frequency of injecting the liquid medicine into the axillary lymph stasis area of the lymph stasis area is 3 months. The first 3 times are treatment periods, and beyond 3 times, a maintenance metabolic period is entered. Wherein, the frequency of injecting the liquid medicine into the axillary lymph stasis and obstruction area of the lymph stasis and obstruction area is 5 times, the frequency of injecting the liquid medicine into the axillary lymph stasis and obstruction area of the axillary. The first 3 times are treatment periods, and beyond 3 times, a maintenance metabolic period is entered.
Example 5
A liquid medicine is used for preparing a medicine for improving body type and posture symptoms, and is injected into a lymph stasis blocking area, and the method comprises the following steps: determining an injection position: selecting the position of the lymph stasis blocking area as an injection position; skin disinfection: disinfecting the skin at the injection site with a sterile cotton swab; liquid medicine injection: and (3) holding the syringe filled with the liquid medicine by hand, evacuating air, aligning the needle tip with the injection position, quickly puncturing the skin, slowly inserting the needle to the needle insertion depth, slowly injecting the liquid medicine, after the liquid medicine is injected, pulling out the needle head of the syringe, and lightly pressing by using a sterile cotton swab to finish injection. Wherein, the frequency of injecting the liquid medicine into the inguinal lymph stasis blocking area of the lymph stasis blocking area is 10 times, the frequency of injection for the first 3 times is 40-60 days, and the frequency of injection for more than 3 times is 3 months. The first 3 times are treatment periods, and beyond 3 times, a maintenance metabolic period is entered.
Example 6
A liquid medicine is used for preparing a medicine for improving body type and posture symptoms, and is injected into a lymph stasis blocking area, and the method comprises the following steps: determining an injection position: selecting the position of the lymph stasis blocking area as an injection position; skin disinfection: disinfecting the skin at the injection site with a sterile cotton swab; liquid medicine injection: and (3) holding the syringe filled with the liquid medicine by hand, evacuating air, aligning the needle tip with the injection position, quickly puncturing the skin, slowly inserting the needle to the needle insertion depth, slowly injecting the liquid medicine, after the liquid medicine is injected, pulling out the needle head of the syringe, and lightly pressing by using a sterile cotton swab to finish injection. The frequency of injecting the liquid medicine into the inguinal lymph stasis blocking area of the lymph stasis blocking area is 10 times, the frequency of injection for the first 3 times is 40-60 days, and the frequency of injection for more than 3 times is 3-4 months. The first 3 times are treatment periods, and beyond 3 times, a maintenance metabolic period is entered. Wherein, the frequency of injecting the liquid medicine into the inguinal lymph stasis blocking area of the lymph stasis blocking area is 5 times, the frequency of injecting the liquid medicine into the inguinal lymph stasis blocking area of the inguinal lymph. The first 3 times are treatment periods, and beyond 3 times, a maintenance metabolic period is entered.
Example 7
A liquid medicine is used for preparing a medicine for improving body type and posture symptoms, and is injected into a shoulder-neck lymph area of a lymph stasis blocking area, and the liquid medicine comprises the following steps: determining an injection position: selecting the position of a shoulder-neck lymph region in a lymph stasis blocking region as an injection position; skin disinfection: disinfecting the skin at the injection site with a sterile cotton swab; liquid medicine injection: and (3) holding the syringe filled with the liquid medicine by hand, evacuating air, aligning the needle tip with the injection position, quickly puncturing the skin, slowly inserting the needle to the needle insertion depth, slowly injecting the liquid medicine, after the liquid medicine is injected, pulling out the needle head of the syringe, and lightly pressing by using a sterile cotton swab to finish injection. The liquid medicine comprises the following raw material components in parts by weight: 1 part of medical collagen filling agent, 2 parts of astragalus injection, 2 parts of compound angelica injection and 100 parts of normal saline.
Example 8
A liquid medicine is used for preparing a medicine for improving body type and posture symptoms, and is injected into a shoulder-neck lymph area of a lymph stasis blocking area, and the liquid medicine comprises the following steps: determining an injection position: selecting the position of a shoulder-neck lymph region in a lymph stasis blocking region as an injection position; skin disinfection: disinfecting the skin at the injection site with a sterile cotton swab; liquid medicine injection: and (3) holding the syringe filled with the liquid medicine by hand, evacuating air, aligning the needle tip with the injection position, quickly puncturing the skin, slowly inserting the needle to the needle insertion depth, slowly injecting the liquid medicine, after the liquid medicine is injected, pulling out the needle head of the syringe, and lightly pressing by using a sterile cotton swab to finish injection. The liquid medicine comprises the following raw material components in parts by weight: 3 parts of medical collagen filling agent, 6 parts of astragalus injection, 6 parts of compound angelica injection and 300 parts of normal saline.
TABLE 1 improvement test for body type and posture improvement of different lymph stasis blocking areas
The test study of the condition of improving body shape and posture after injection was conducted by using volunteers as test subjects, and the influence of the injection solutions of examples 1 to 4 on the improvement of body shape and posture under the test conditions was examined. The specific operation method is as follows:
Determining an injection position: selecting the position of the shoulder and neck lymph as an injection position; skin disinfection: disinfecting the skin at the injection site with a sterile cotton swab; when the liquid medicine is injected, the liquid medicine is prepared as follows: and (3) holding the syringe filled with the liquid medicine by hand, evacuating air, aligning the needle tip with the injection position, quickly puncturing the skin, slowly inserting the needle to the needle insertion depth, slowly injecting the liquid medicine, after the liquid medicine is injected, pulling out the needle head of the syringe, and lightly pressing by using a sterile cotton swab to finish injection. After the liquid medicine is obtained, the needle is inserted into the subcutaneous tissue with the depth of 3-5 cm and the inclined angle of 60-90 degrees with the surface of the skin. It should be noted that the volume of the liquid medicine injected into the shoulder-neck lymph area at one time is not more than 120 ml. Injecting a liquid medicine into the lymph stasis blocking area comprises: inguinal lymph stasis region, shoulder and neck lymph region, and axillary lymph stasis region.
TABLE 1
TABLE 2 improvement test for improving body type and posture
The test study of the condition of improving body shape and posture after injection was conducted by using volunteers as test subjects, and the influence of the injection solutions of examples 1 to 4 on the improvement of body shape and posture under the test conditions was examined. The specific operation method is as follows:
Determining an injection position: selecting the position of the shoulder and neck lymph as an injection position; skin disinfection: disinfecting the skin at the injection site with a sterile cotton swab; when the liquid medicine is injected, the liquid medicine is prepared as follows: and (3) holding the syringe filled with the liquid medicine by hand, evacuating air, aligning the needle tip with the injection position, quickly puncturing the skin, slowly inserting the needle to the needle insertion depth, slowly injecting the liquid medicine, after the liquid medicine is injected, pulling out the needle head of the syringe, and lightly pressing by using a sterile cotton swab to finish injection. After the liquid medicine is obtained, the needle is inserted into the subcutaneous tissue with the depth of 3-5 cm and the inclined angle of 60-90 degrees with the surface of the skin. It should be noted that the volume of the liquid medicine injected into the shoulder-neck lymph area at one time is not more than 120 ml. The injection of the liquid medicine to the lymph stasis blocking area comprises the following steps: the shoulder and neck lymph regions.
TABLE 2
The above description is only a preferred embodiment of the present application and is not intended to limit the present application, and various modifications and changes may be made by those skilled in the art. Any modification, equivalent replacement, improvement and the like made within the spirit and principle of the present application shall be included in the protection scope of the present application.

Claims (4)

1. The application of a liquid medicine in preparing a medicine for improving body type and posture symptoms is characterized by comprising the liquid medicine, wherein the liquid medicine injected into a lymph stasis blocking area comprises the following raw material components in parts by weight: 1-3 parts of medical collagen filling agent, 2-6 parts of astragalus injection, 2-6 parts of compound angelica injection and 100-300 parts of normal saline.
2. The application of the liquid medicine according to claim 1 in preparing a medicament for improving body type and posture symptoms, which is characterized by comprising the following raw material components in parts by weight: 1 part of medical collagen filling agent, 2 parts of astragalus injection, 2 parts of compound angelica injection and 100 parts of normal saline.
3. The use of the medical solution according to claim 1 for the preparation of a medicament for improving body shape and posture symptoms, wherein the medical collagen filler is a physiological saline suspension of 3.5% bovine collagen and 0.3% lidocaine hydrochloride.
4. The use of the liquid medicine according to claim 1 for preparing a medicament for improving body shape and posture symptoms, wherein the effective components of the compound angelica injection are angelica, ligusticum chuanxiong hort and safflower.
CN201910194565.0A 2019-03-14 2019-03-14 Application of liquid medicine in preparing medicine for improving body shape and posture symptoms Pending CN110559484A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201910194565.0A CN110559484A (en) 2019-03-14 2019-03-14 Application of liquid medicine in preparing medicine for improving body shape and posture symptoms

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201910194565.0A CN110559484A (en) 2019-03-14 2019-03-14 Application of liquid medicine in preparing medicine for improving body shape and posture symptoms

Publications (1)

Publication Number Publication Date
CN110559484A true CN110559484A (en) 2019-12-13

Family

ID=68773448

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201910194565.0A Pending CN110559484A (en) 2019-03-14 2019-03-14 Application of liquid medicine in preparing medicine for improving body shape and posture symptoms

Country Status (1)

Country Link
CN (1) CN110559484A (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1634250A (en) * 2004-10-18 2005-07-06 四川乐山三民药物科技开发有限公司 Compound injectio of Chinese angelica and astragalus root and its preparing process
CN102579560A (en) * 2010-05-29 2012-07-18 甘肃中医学院 Preparation method of Chinese angelica and astragalus mongholicus mixture aqueous extract, as well as application in intervening in pulmonary fibrosis
CN105031726A (en) * 2015-09-02 2015-11-11 长春博泰医药生物技术有限责任公司 Medical collagen filling agent
CN105902604A (en) * 2016-05-20 2016-08-31 武汉理工大学 Compound medicament for treating T-cell acute lymphoblastic leukemia (T-ALL)

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1634250A (en) * 2004-10-18 2005-07-06 四川乐山三民药物科技开发有限公司 Compound injectio of Chinese angelica and astragalus root and its preparing process
CN102579560A (en) * 2010-05-29 2012-07-18 甘肃中医学院 Preparation method of Chinese angelica and astragalus mongholicus mixture aqueous extract, as well as application in intervening in pulmonary fibrosis
CN105031726A (en) * 2015-09-02 2015-11-11 长春博泰医药生物技术有限责任公司 Medical collagen filling agent
CN105902604A (en) * 2016-05-20 2016-08-31 武汉理工大学 Compound medicament for treating T-cell acute lymphoblastic leukemia (T-ALL)

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
兰长贵等: "《皮肤病学的理论与实践》", 30 May 2009, 四川科学技术出版社 *
李世文: "《老药新用途》", 30 January 2017 *
李冰: "血必净注射液对脓毒症大鼠肠系膜微循环动态变化的影响", 《中国全科医学》 *
李振全等: "《滞动针疗法》", 30 January 2016, 中国中医药出版社 *
雷燕等: "黄芪、当归及其组方促血管内皮细胞增殖作用的研究", 《中国中西医结合杂志》 *

Similar Documents

Publication Publication Date Title
CN104043045B (en) Treat the pharmaceutical composition of optic atrophy
CN112915173A (en) Traditional Chinese medicine composition for treating orthopedic diseases, preparation method and application
Dean A Report ON TWENTY-FIVE CASES OF TETANUS.:(To the Medical Research Committee.)
CN110559484A (en) Application of liquid medicine in preparing medicine for improving body shape and posture symptoms
CN104547093A (en) Traditional Chinese medicine composition for treating tenosynovitis
CN110743037A (en) Application of hydro-acupuncture liquid medicine in preparing medicine for relieving shoulder and neck disease symptoms
CN110604834A (en) Application of hydro-acupuncture liquid medicine in preparation of medicine for treating lymph stasis and obstruction areas
CN105998553A (en) Traditional Chinese medicine for treating traumatic injury and fracture
CN103211978B (en) Chinese medicine composition for treating kidney-yang deficiency type aplastic anemia
CN111760012A (en) Traditional Chinese medicine composition with health care function and preparation method and application thereof
CN110538362A (en) Application of nutrient solution in preparation of medicine for treating lymphatic stasis regional disease symptoms
CN104800663A (en) Traditional Chinese medicinal liquor for treating hyperostosis and preparation method of traditional Chinese medicinal liquor
CN104606455B (en) A kind of medicament for the treatment of lumbar muscle strain
CN109529022A (en) A kind of diabetic foot wound externally applied drug and its application method
CN1164287C (en) Composite Chinese medicine powder for treating burns and scalds
CN1141967C (en) Externally applied Chinese medicine oil prepn for treating burns and scalds
KR102335712B1 (en) Composition for lipolysis and injection apparatus thereof
RU2746035C1 (en) Method for pain syndrome alleviation after breast endoproshetics
CN1981865A (en) Formula and usage for treating acne
RU2354383C2 (en) Method of treating peroneal syndrome
HAN et al. 30 cases of popliteal cyst treated by fire needling and cupping therapy
RU2286162C1 (en) Method for treating skin manifestations of scleroderma
She Time selection of acupuncture treatment for facial paralysis
Yue Observation of Therapeutic Effect of Hirudoid Ointment on Infantile Phlebitis Caused by Intravenous Indwelling Needle.
CN110604809A (en) Application of liquid medicine in preparation of medicine for improving symptoms of Fugui bag

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination